Enhance your patent search with AI. Try the FREE AI-powered tool

2023 U.S. Pharmaceuticals Patent Landscape

2023 U.S. Pharmaceuticals Patent Landscape

2023 U.S. Pharmaceuticals Patent Landscape

The U.S. pharmaceutical industry witnessed various achievements in vaccines, cancer treatments, and other transformative drugs in the past year. While still performing below the index, the major success by Novo Nordisk with their semaglutide drugs Ozempic, Wegovy, and Rybelsus could trigger more innovations in what can be considered a high-risk area for investment, but has large patient populations.

Our patent landscape report focuses on the analysis of U.S. patents and patent applications (PPAs) relating to pharmaceuticals that were published in 2023. The search resulted in a dataset of 21,235 US PPAs. In our analysis, we focused on the top diseases and drug targets, and zeroed in on the top 10 patent applicants in the pharmaceutical space and featured some of their key patent applications for 2023. Diabetes, respiratory diseases and cancer are the top areas in innovation. The University of California, Roche, INSERM, Novartis, and Sanofi are among the leading patent applicants in the U.S. (based on number of patent filings published).  Download our U.S. Pharmaceuticals Patent Landscape Report for free.

Know the landscape. Get ahead.

Get customized, comprehensive patent landscape reports on your chosen technology area.

Subscribe to our newsletter

  • Questions? Check our privacy policy.
  • This field is for validation purposes and should be left unchanged.

Sign up to get access

"*" indicates required fields

Name*
By signing, you accept Parola Analytics terms of service and privacy policy, and agree to receive occasional email about campaigns. you can unsubscribe anytime.
Hidden
Hidden
This field is for validation purposes and should be left unchanged.

Patent and IP updates straight to your inbox

Sign up now to receive monthly patent news, analysis and free insight reports.

We don’t spam, we promise.

Disclaimer: 

1. Parola Analytics and Avontis are distinct entities and operate independently. Any references to Avontis or its services do not constitute a legal partnership. 

2. Parola Analytics does not provide legal services. Our services are limited to research and technical analysis. Any information provided by Parola Analytics should not be construed as legal advice.